Evidence map›Paper›PMID 40735048›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Amyloid accumulation, brain atrophy, and cognitive decline in emergent Alzheimer's disease.

Ying Xia, Pierrick Bourgeat, Vincent Doré, Jurgen Fripp, Yen Ying Lim, Simon M Laws, Christopher Fowler, Christopher C Rowe, Colin L Masters, Elizabeth J Coulson and 2 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ying XiaThe Australian e-Health Research Centre CSIRO Health and Biosecurity Herston Queensland Australia.ORCID https://orcid.org/0000-0003-3107-7759
Pierrick BourgeatThe Australian e-Health Research Centre CSIRO Health and Biosecurity Herston Queensland Australia.
Vincent DoréAustin Health Heidelberg Victoria Australia.
Jurgen FrippThe Australian e-Health Research Centre CSIRO Health and Biosecurity Herston Queensland Australia.
Yen Ying LimTurner Institute of Brain and Mental Health School of Psychological Sciences Monash University Clayton Victoria Australia.
Simon M LawsCentre for Precision Health Edith Cowan University Joondalup Western Australia Australia.
Christopher FowlerThe Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia.
Christopher C RoweAustin Health Heidelberg Victoria Australia.
Colin L MastersThe Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia.
Elizabeth J CoulsonSchool of Biomedical Sciences The University of Queensland St Lucia Queensland Australia.
Paul MaruffThe Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia.
AIBL Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEmergent Alzheimer's disease (AD) represents a transitional stage where cognitively unimpaired (CU) individuals exhibit subthreshold but increasing amyloid-β (Aβ) levels. The impact of Aβ accumulation on brain volume loss and cognition during this early stage remains unclear.

methodsThis retrospective cohort study analyzed data from 408 CU participants who were initially Aβ- (< 15 Centiloids) and followed for up to 15 years. Changes in basal forebrain and hippocampal volume, along with domain-specific cognitive performance, were compared between those who progressed to Aβ+ (≥20 Centiloids) and those who remained Aβ-.

resultsSixty-five CU participants progressed to Aβ+, indicating emergent AD, and showed faster Aβ accumulation and subtle memory decline. However, no significant differences in rate of BF and hippocampal atrophy were observed between groups. DISCUSSION: The results suggest that during this emergent phase of AD, Aβ accumulation is associated with episodic memory loss, in the absence of detectable accelerated brain atrophy. Highlights: Identified cognitively unimpaired individuals in the emergent stage of Alzheimer's disease (AD).Emergent AD exhibits a greater rate of amyloid-β (Aβ) accumulation.No accelerated volume loss detected in the basal forebrain or hippocampus.Emergent AD is also associated with a subtle decline in memory.Early Aβ accumulation may impair cognitive function before structural atrophy.

Indexed as

Alzheimer's diseaseamyloid accumulationbasal forebraincognitive declinelongitudinal studyMRI

Identifiers

PMID40735048
PMCPMC12305117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.